This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Avanir Pharmaceuticals Announces Multiple Data Presentations Related To Pseudobulbar Affect (PBA) Prevalence And Treatment At Two Conferences In June

ALISO VIEJO, Calif., May 30, 2014 /PRNewswire/ --  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the prevalence and treatment of pseudobulbar affect (PBA), a distressing neurological condition characterized by uncontrollable laughing or crying, will be presented at the following conferences in June.

Avanir Pharmaceuticals, Inc.

Joint Congress of European Neurology (EFNS-ENS), May 31 - June 3, 2014, Istanbul

  • Burden of pseudobulbar affect (PBA) symptoms in veterans with traumatic brain injury (TBI)
    • Abstract Number: A-635-0018-01071
    • Poster Session: Neuro-epidemiology; Neurorehabilitation
    • Time: June 1 at 12:30 p.m. EEST
  • Dextromethorphan/Quinidine (DMQ) treatment significantly increased percentage of days free of pseudobulbar affect (PBA) episodes in a phase 3, randomized, placebo-controlled trial
    • Abstract Number: A-635-0005-02074
    • Poster Session: Clinical neurophysiology
    • Time: June 1 at 12:30 p.m. EEST
  • Dextromethorphan/Quinidine for treatment of pseudobulbar affect: analysis of treatment-related adverse events
    • Abstract Number: A-635-0005-02075
    • Poster Session: Clinical neurophysiology
    • Time: June 1 at 12:30 p.m. EEST
  • Time to sustained remission of pseudobulbar affect (PBA) episodes after treatment with dextromethorphan and quinidine
    • Abstract Number: A-635-0005-02618
    • Poster Session: Clinical neurophysiology
    • Time: June 1 at 12:30 p.m. EEST

International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 31 - June, 4, 2014, Montreal
  • Screening for PBA Symptoms Using a Single Question vs. a 7 Question Measure and Assessment of the Association of PBA Symptoms with HRQOL Burden
    • Abstract Number: PND45
    • Session: Research Posters Session I
    • Time: June 2 at 1:15 p.m. EDT

About PBAPBA is a neurologic condition characterized by uncontrollable, disruptive laughing and/or crying outbursts that are often contrary or exaggerated to the patient's inner mood state. As a result, many of those afflicted with PBA show significant impairment on standard measures of health status, and impairments in occupational and social function, often leading to social isolation. PBA occurs secondary to a variety of neurologic conditions such as traumatic brain injury (TBI), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Parkinson's disease, stroke and Alzheimer's disease. When these disorders damage areas of the brain that regulate normal emotional expression, they can lead to uncontrollable, disruptive episodes of crying or laughing. For more information about PBA, please visit

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs